Patricia A Bradford

List of Publications by Year
in descending order

100 papers	10,965 citations	38720 50 h-index	39638 94 g-index
100 all docs	100 docs citations	100 times ranked	9078 citing authors

#	Article	IF	Citations
1	Consensus on Î²-Lactamase Nomenclature. Antimicrobial Agents and Chemotherapy, 2022, 66, e0033322.	1.4	11
2	A Tribute to George A. Jacoby. Antimicrobial Agents and Chemotherapy, 2022, , e0049822.	1.4	0
3	The primary pharmacology of ceftazidime/avibactam: in vitro translational biology. Journal of Antimicrobial Chemotherapy, 2022, 77, 2321-2340.	1.3	4
4	The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD). Journal of Antimicrobial Chemotherapy, 2022, 77, 2341-2352.	1.3	9
5	Extended-spectrum Î²-lactamases: an update on their characteristics, epidemiology and detection. JAC-Antimicrobial Resistance, 2021, 3, dlab092.	0.9	256
6	A Standard Numbering Scheme for Class C Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	50
7	In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017â€“2018. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1559-1572.	1.3	11
8	Epidemiology of Î²-Lactamase-Producing Pathogens. Clinical Microbiology Reviews, 2020, 33, .	5.7	425
9	Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates. ACS Infectious Diseases, 2020, 6, 1332-1345.	1.8	73
10	In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	8
11	Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	21
12	Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin. Journal of Clinical Microbiology, 2019, 57, .	1.8	7
13	mSphere of Influence: the View from the Microbiologists of the Future. MSphere, 2019, 4, .	1.3	0
14	Characterization of Î²-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against Î²-Lactamase Producers. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	21
15	Interplay between Î²-lactamases and new Î²-lactamase inhibitors. Nature Reviews Microbiology, 2019, 17, 295-306.	13.6	322
16	Molecular Î²-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. International Journal of Antimicrobial Agents, 2018, 52, 287-292.	1.1	26
17	In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	13
18	Antibioticsâ€”From There to Where?. Pathogens and Immunity, 2018, 3, 19.	1.4	51

#	Article	IF	Citations
19	Epidemiology of Bacterial Resistance. , 2018, , 299-339.		0
20	In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	70
21	A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	14
22	Genomic Epidemiology of Global Carbapenemase-ProducingEnterobacterspp., 2008â€“2014. Emerging Infectious Diseases, 2018, 24, 1010-1019.	2.0	107
23	Genomic characterization of IMP and VIM carbapenemase-encoding transferable plasmids of Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2018, 73, 3034-3038.	1.3	33
24	Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914. Diagnostic Microbiology and Infectious Disease, 2017, 87, 139-142.	0.8	5
25	In vitroactivity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw561.	1.3	22
26	Importance of Clonal Complex 258 and IncF _{K2-like} Plasmids among a Global Collection of Klebsiella pneumoniae with bla _{KPC}. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	59
27	Genomic epidemiology of global VIM-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, 2249-2258.	1.3	47
28	In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	129
29	Molecular Î²-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	31
30	In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	24
31	GlobalEscherichia coliSequence Type 131 Clade withbla_{CTX-M-27}Gene. Emerging Infectious Diseases, 2016, 22, 1900-1907.	2.0	146
32	Î²-Lactams and Î²-Lactamase Inhibitors: An Overview. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a025247.	2.9	663
33	Global Dissemination of bla _{KPC} into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam. Antimicrobial Agents and Chemotherapy, 2016, 60, 4490-4500.	1.4	78
34	Structural and sequence analysis of class A Î²-lactamases with respect to avibactam inhibition: impact of Î©-loop variations. Journal of Antimicrobial Chemotherapy, 2016, 71, 2848-2855.	1.3	26
35	Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893. Antimicrobial Agents and Chemotherapy, 2016, 60, 5312-5321.	1.4	41
36	Correlation of Î²-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program. Antimicrobial Agents and Chemotherapy, 2016, 60, 1385-1392.	1.4	81

#	Article	IF	Citations
37	Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-Î²-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2016, 60, 1067-1078.	1.4	171
38	Pharmacokinetics/pharmacodynamics of a Î²-lactam and Î²-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. Journal of Antimicrobial Chemotherapy, 2015, 70, 2618-2626.	1.3	70
39	In Vitro Activity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013. Antimicrobial Agents and Chemotherapy, 2015, 59, 4239-4248.	1.4	111
40	In Vitro Antibacterial Activity of AZD0914, a New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-Positive, Fastidious Gram-Negative, and Atypical Bacteria. Antimicrobial Agents and Chemotherapy, 2015, 59, 467-474.	1.4	67
41	In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy, 2015, 59, 6053-6063.	1.4	18
42	Global Incidence of Carbapenemase-ProducingEscherichia coliST131. Emerging Infectious Diseases, 2014, 20, 1928-1931.	2.0	99
43	Tetracyclines. , 2012, , 147-179.		3
44	RT-PCR and Statistical Analyses ofadeABCExpression in Clinical Isolates ofAcinetobacter calcoaceticusâ€“Acinetobacter baumanniiComplex. Microbial Drug Resistance, 2010, 16, 87-89.	0.9	43
45	Identification of CTX-M Î²-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagnostic Microbiology and Infectious Disease, 2010, 66, 402-406.	0.8	34
46	Identification of Plasmid-Mediated AmpC Î²-Lactamases in Escherichia coli , Klebsiella spp., and Proteus Species Can Potentially Improve Reporting of Cephalosporin Susceptibility Testing Results. Journal of Clinical Microbiology, 2009, 47, 294-299.	1.8	38
47	Efficacy of Piperacillin Combined with the Penem Î²-Lactamase Inhibitor BLI-489 in Murine Models of Systemic Infection. Antimicrobial Agents and Chemotherapy, 2009, 53, 1698-1700.	1.4	26
48	Characterization and Sequence Analysis of Extended-Spectrum-Î²-Lactamase-Encoding Genes from Escherichia coli, Klebsiella pneumoniae , and Proteus mirabilis Isolates Collected during Tigecycline Phase 3 Clinical Trials. Antimicrobial Agents and Chemotherapy, 2009, 53, 465-475.	1.4	56
49	Pyrosequencing Using the Single-Nucleotide Polymorphism Protocol for Rapid Determination of TEM- and SHV-Type Extended-Spectrum Î²-Lactamases in Clinical Isolates and Identification of the Novel Î²-Lactamase Genes bla _{SHV-48} , bla _{SHV-105} , and bla _{TEM-155}. Antimicrobial Agents and Chemotherapy, 2009, 53, 977-986.	1.4	27
50	Establishment of In Vitro Susceptibility Testing Methodologies and Comparative Activities of Piperacillin in Combination with the Penem Î²-Lactamase Inhibitor BLI-489. Antimicrobial Agents and Chemotherapy, 2009, 53, 370-384.	1.4	20
51	Comment on: Redefining extended-spectrum Â-lactamases: balancing science and clinical need. Journal of Antimicrobial Chemotherapy, 2009, 64, 212-213.	1.3	18
52	Recent Developments in Î²-Lactamases and Inhibitors. Annual Reports in Medicinal Chemistry, 2008, 43, 247-267.	0.5	10
53	CarbapenemâEResistantEscherichia coliHarboringKlebsiella pneumoniaeCarbapenemase Î²â€Lactamases Associated with Longâ€Term Care Facilities. Clinical Infectious Diseases, 2008, 46, e127-e130.	2.9	82
54	Real-Time PCR and Statistical Analyses of acrAB and ramA Expression in Clinical Isolates of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2008, 52, 3430-3432.	1.4	45

#	Article	IF	Citations
55	Resistance of Gram-Negative Bacilli to Antimicrobials. , 2008, , 97-159.		3
56	Validation and Reproducibility Assessment of Tigecycline MIC Determinations by Etest. Journal of Clinical Microbiology, 2007, 45, 2474-2479.	1.8	34
57	AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticusâ€“Acinetobacter baumannii complex. Journal of Antimicrobial Chemotherapy, 2007, 59, 1001-1004.	1.3	218
58	Occurrence of Tetracycline Resistance Genes among Escherichia coli Isolates from the Phase 3 Clinical Trials for Tigecycline. Antimicrobial Agents and Chemotherapy, 2007, 51, 3205-3211.	1.4	71
59	MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. Journal of Antimicrobial Chemotherapy, 2007, 61, 46-53.	1.3	142
60	In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth. Diagnostic Microbiology and Infectious Disease, 2007, 59, 347-349.	0.8	52
61	Late stage antibacterial drugs in the clinical pipeline. Current Opinion in Microbiology, 2007, 10, 441-446.	2.3	78
62	RamA, a Transcriptional Regulator, and AcrAB, an RND-Type Efflux Pump, are Associated with Decreased Susceptibility to Tigecycline inEnterobacter cloacae. Microbial Drug Resistance, 2007, 13, 1-6.	0.9	95
63	Functional, Biophysical, and Structural Bases for Antibacterial Activity of Tigecycline. Antimicrobial Agents and Chemotherapy, 2006, 50, 2156-2166.	1.4	171
64	Identification and Sequence of a tet (M) Tetracycline Resistance Determinant Homologue in Clinical Isolates of Escherichia coli. Journal of Bacteriology, 2006, 188, 7151-7164.	1.0	37
65	Diagnostic PCR Analysis of the Occurrence of Methicillin and Tetracycline Resistance Genes among Staphylococcus aureus Isolates from Phase 3 Clinical Trials of Tigecycline for Complicated Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy, 2006, 50, 505-510.	1.4	54
66	In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. Journal of Antimicrobial Chemotherapy, 2006, 57, 573-576.	1.3	231
67	In Vitro Activity of Tigecycline against Isolates from Patients Enrolled in Phase 3 Clinical Trials of Treatment for Complicated Skin and Skinâ€Structure Infections and Complicated Intraâ€Abdominal Infections. Clinical Infectious Diseases, 2005, 41, S315-S332.	2.9	124
68	Use of Ribotyping To Retrospectively Identify Methicillin-Resistant Staphylococcus aureus Isolates from Phase 3 Clinical Trials for Tigecycline That Are Genotypically Related to Community-Associated Isolates. Antimicrobial Agents and Chemotherapy, 2005, 49, 4521-4529.	1.4	27
69	A Novel MATE Family Efflux Pump Contributes to the Reduced Susceptibility of Laboratory-Derived Staphylococcus aureus Mutants to Tigecycline. Antimicrobial Agents and Chemotherapy, 2005, 49, 1865-1871.	1.4	218
70	Influence of Transcriptional Activator RamA on Expression of Multidrug Efflux Pump AcrAB and Tigecycline Susceptibility in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2005, 49, 1017-1022.	1.4	181
71	Tigecycline MIC Testing by Broth Dilution Requires Use of Fresh Medium or Addition of the Biocatalytic Oxygen-Reducing Reagent Oxyrase To Standardize the Test Method. Antimicrobial Agents and Chemotherapy, 2005, 49, 3903-3909.	1.4	96
72	Effect of Medium Age and Supplementation with the Biocatalytic Oxygen-Reducing Reagent Oxyrase on In Vitro Activities of Tigecycline against Recent Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2005, 49, 3910-3918.	1.4	42

#	Article	IF	Citations
73	AcrAB Efflux Pump Plays a Role in Decreased Susceptibility to Tigecycline in Morganella morganii. Antimicrobial Agents and Chemotherapy, 2005, 49, 791-793.	1.4	80
74	In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagnostic Microbiology and Infectious Disease, 2005, 51, 291-295.	0.8	50
75	Comparative In Vitro Activities of AC98-6446, a Novel Semisynthetic Glycopeptide Derivative of the Natural Product Mannopeptimycin Î±, and Other Antimicrobial Agents against Gram-Positive Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 739-746.	1.4	55
76	Emergence of Carbapenem-Resistant Klebsiella Species Possessing the Class A Carbapenem-Hydrolyzing KPC-2 and Inhibitor-Resistant TEM-30 Â-Lactamases in New York City. Clinical Infectious Diseases, 2004, 39, 55-60.	2.9	453
77	Tigecycline: a first in class glycylcycline. Clinical Microbiology Newsletter, 2004, 26, 163-168.	0.4	36
78	Mechanism of Action of the Mannopeptimycins, a Novel Class of Glycopeptide Antibiotics Active against Vancomycin-Resistant Gram-Positive Bacteria. Antimicrobial Agents and Chemotherapy, 2004, 48, 728-738.	1.4	114
79	Hydrophobic Acetal and Ketal Derivatives of Mannopeptimycin-Î± and Desmethylhexahydromannopeptimycin-Î±:Â Semisynthetic Glycopeptides with Potent Activity Against Gram-Positive Bacteria. Journal of Medicinal Chemistry, 2004, 47, 3487-3490.	2.9	37
80	Determining incidence of extended spectrum Î²-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001â€“2002. International Journal of Antimicrobial Agents, 2004, 24, 119-124.	1.1	112
81	In Vitro and In Vivo Activities of Novel 6-Methylidene Penems as Î²-Lactamase Inhibitors. Antimicrobial Agents and Chemotherapy, 2004, 48, 4589-4596.	1.4	51
82	Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus. Biochimica Et Biophysica Acta - General Subjects, 2003, 1621, 117-121.	1.1	56
83	In Vitro Activity of Tigecycline against Staphylococcus epidermidis Growing in an Adherent-Cell Biofilm Model. Antimicrobial Agents and Chemotherapy, 2003, 47, 3967-3969.	1.4	48
84	AcrAB Multidrug Efflux Pump Is Associated with Reduced Levels of Susceptibility to Tigecycline (GAR-936) in Proteus mirabilis. Antimicrobial Agents and Chemotherapy, 2003, 47, 665-669.	1.4	153
85	Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrobial Agents and Chemotherapy, 2003, 47, 972-978.	1.4	267
86	In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens. Antimicrobial Agents and Chemotherapy, 2002, 46, 2595-2601.	1.4	165
87	Further Evidence that a Cell Wall Precursor [C55-MurNAc-(Peptide)-GlcNAc] Serves as an Acceptor in a Sorting Reaction. Journal of Bacteriology, 2002, 184, 2141-2147.	1.0	81
88	Molecular Epidemiology of a Citywide Outbreak of Extendedâ€Spectrum Î²â€Lactamaseâ€“ProducingKlebsiella pneumoniaeInfection. Clinical Infectious Diseases, 2002, 35, 834-841.	2.9	89
89	Identification of Compounds That Inhibit Late Steps of Peptidoglycan Synthesis in Bacteria.. Journal of Antibiotics, 2002, 55, 288-295.	1.0	30
90	Extended-Spectrum Î²-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clinical Microbiology Reviews, 2001, 14, 933-951.	5.7	2,099

#	Article	IF	Citations
91	Whatâ€™s new in Î²-lactamases?. Current Infectious Disease Reports, 2001, 3, 13-19.	1.3	19
92	Ceftriaxone-Resistant Salmonella Infection Acquired by a Child from Cattle. New England Journal of Medicine, 2000, 342, 1242-1249.	13.9	481
93	Automated Thermal Cycling Is Superior to Traditional Methods for Nucleotide Sequencing of bla _{SHV} Genes. Antimicrobial Agents and Chemotherapy, 1999, 43, 2960-2963.	1.4	34
94	Clinical Characteristics and Molecular Epidemiology Associated with Imipenemâ€Resistant Klebsiella pneumoniae. Clinical Infectious Diseases, 1999, 29, 352-355.	2.9	58
95	Multiple Antibioticâ€“Resistant <EMPH TYPE="ITAL">Klebsiella</EMPH> and <EMPH TYPE="ITAL">Escherichia coli</EMPH> in Nursing Homes. JAMA - Journal of the American Medical Association, 1999, 281, 517.	3.8	424
96	Characterization of expanded-spectrum cephalosporin resistance in E. coli isolates associated with bovine calf diarrhoeal disease. Journal of Antimicrobial Chemotherapy, 1999, 44, 607-610.	1.3	80
97	Ceftazidime-Resistant Klebsiella pneumoniae and Escherichia coli Isolates Producing TEM-10 and TEM-43 Î²-Lactamases from St. Louis, Missouri. Antimicrobial Agents and Chemotherapy, 1998, 42, 1671-1676.	1.4	51
98	CTX-M-5, a Novel Cefotaxime-Hydrolyzing Î²-Lactamase from an Outbreak of Salmonella typhimurium in Latvia. Antimicrobial Agents and Chemotherapy, 1998, 42, 1980-1984.	1.4	139
99	PROBLEMS WITH DETECTION OF Î²-LACTAM RESISTANCE AMONG NONFASTIDIOUS GRAM-NEGATIVE BACILLI. Infectious Disease Clinics of North America, 1993, 7, 411-424.	1.9	4
100	Î²-Lactamases: Historical Perspectives. , 0, , 65-79.		3